Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 4890 other investors.
Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement.
We given an initial take on Nexstim’s H2 report, that further proved Nexstim’s capability to turn the company profitable.
Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medical and gives an initial take.
We give a short comment on the results from Nexstim’s pilot study in chronic pain.
Since our initiation of coverage, Nexstim has continued to deliver solid and higher-than-expected growth in its key segments of diagnostics and therapeutics.
Redeye has a positive take on the news that Nexstim has launched a combined NBS/NBT system in the US. We give a short comment.
We give our take on today’s H1 report from Nexstim. We are overall pleased with the developments in Nexstim so far this year, as sales exceeded our estimates with significant growth across the board.
Nexstim announced today that its ongoing pilot study using an accelerated TMS protocol to treat chronic neuropathic pain has been slightly delayed due to the pandemic. The company will continue to recruit patients during Q3 (previously H1).